Removal of anti-NCA activity from the CEA antiserum was assessed by applying the unabsorbed and absorbed antisera to blood smears prepared from a patient with chronic granulocytic. leukaemia and to sections of normal spleen." Sections of normal colon, stomach, breast, and prostate were negative controls, while sections of carcinomas of these tissues were positive controls for absorbed antiserum. Normal trephine biopsies from patients with nonmalignant conditions were also included. Slides of all control specimens were included in each staining batch.
Few patients with carcinomas have demonstrable metastases in the bone marrow. In an examination of bone marrow specimens taken from 2191 such patients only 8-5% showed metastatic tumour using conventional stains. ' Multiple biopsies, multiple sections, and the simultaneous use of aspirates, clot sections, and trephine biopsies have all been used in attempts to increase the detection rate. More recently, immunochemical stains have been introduced for specific tumour antigens. Metastatic adenocarcinoma expressing carcinoembryonic antigen (CEA) has been shown in regional lymph nodes from patients with colonic and breast carcinoma,23 and Cal antibody has been used to distinguish malignant from non-malignant cells in serous fluids. 4 Immunochemical detection of epithelial membrane antigen in sections of bone marrow aspirate has yielded an increased number of positive samples and shown a greater extent of tumour infiltration.5 In the present study, tumour tissue and bone marrow samples from patients with carcinomas of varying origin were stained for CEA using an immunoperoxidase method.
Patients and methods

PATIENTS
Twenty patients with carcinomas were studied. A Tc-99m radioisotope bone scan and chest x ray examination were performed and painful bony areas were also examined radiographically. Scans Complete absorption of anti-NCA activity from the CEA antiserum by human spleen extract was shown by the failure of the antiserum to stain sections of normal spleen and smears of chronic granulocytic leukaemia. Sections of normal colon, stomach, breast, prostate,, and bone marrow trephine biopsies also gave a negative reaction for CEA. Positive staining cells in sections of primary and secondary carcinoma and bone marrow trephine biopsies were a distinct yellow-brown viewed against the light blue background of the surrounding tissue. (Figure (a, b) ). Free stain deposit was noted occasionally but was easily identified by careful focusing.
Fifteen of 19 primary tumours had positive reactions for CEA; the least number of positive reac- tions was found in sections of prostatic carcinoma (Tables 1-3 ). Sections of one primary tumour were not available for study. Metastatic tumour was biopsied in nine cases, of which six had positive and two had negative primary tumours. Six of these metastatic tumours were CEA positive, of which four had positive primary tumours. Only one patient had a CEA positive primary tumour with negative metastases. Patient data have been tabulated in three groups on the basis of bone marrow staining. Tumour deposits were identified by haematoxylin and eosin staining in six of 20 marrows (Table 1) . Five of these had CEA positive cells in both the primary tumour and in the marrow, while the sixth patient had a primary carcinoma of the prostate which was CEA negative. The median plasma CEA concentration was 70*0 ,ig/l. Four patients had both radiological and radioisotopic evidence of bony metastases. Table 2 gives details of five patients in whom bone marrow trephine biopsies showed no evidence of tumour metastases on haematoxylin and eosin staining but contained single CEA positive cells which were dispersed throughout the sample (Figure (c,  d) ). Morphologically, these cells were not obviously malignant; nor could they be identified on review of conventionally stained marrow sections. The median plasma CEA concentration was 210 0,g/l; only two patients had evidence of bony metastases on either isotope bone scan or x ray film.
Nine patients had no tumour metastases or CEA positive cells within the marrow (Table 3 ). The median plasma CEA concentration was 27-9 ,ug/l; evidence of bony metastases was present in only three patients, who had positive isotope bone scans or x ray films.
Discussion
The incidence of histologically confirmed bone marrow metastases in patients with carcinoma is variable. ' 12 13 This may reflect a low frequency of marrow involvement, the disease stage when the marrow was examined, or sampling error. It may also arise from difficulty in identifying small amounts of tumour tissue, especially single cells, within the marrow. A tumour marker which reliably demonstrates these cells might profoundly alter both the management and prognosis in these patients.
The immunoperoxidase (indirect peroxidaseantiperoxidase) technique is a highly sensitive method of demonstrating CEA in paraffin embedded tissues. '4 '5 Both the specificity of the antiserum and the use of proper controls are critical to the correct interpretation of results3 and are especially important in the application of this staining method to bone marrow which contains appreciable amounts of NCA, a glycoprotein which shares some antigenic determinants with CEA. NCA has been found in maturing granulocytes" and macrophages and monocytes'6; erythroblasts do not stain for NCA. CEA is minimal or absent in all blood and bone marrow cells." This study has clearly shown that CEA positive tumours maintain their capacity to express the antigen within the environment of the bone marrow having withstood the fixing and decalcifying process undergone by trephine biopsies. The extraordinary stability of the antigen can be gauged by its demonstration in a primary tumour (Table 1) which was excised 12 years before CEA was first described by Gold and Freedman.'7 This confirms the feasibility of retrospective studies.
The marrows of five patients which contained single, CEA positive cells not identified in conventionally stained sections are intriguing but must be interpreted with caution. A morphological resemblance of some of these cells to erythroblasts and other normal constituents of marrow was noted, raising the possibility of false positive reactivity. This was considered implausible for the following reasons:
1 Similar cells were not seen in either control marrows or the marrows from nine other patients with carcinoma (Table 3) . Indeed the vast proportion of haemopoietic tissue in the marrows in which these cells were seen was CEA negative. As stated above, erythroblasts do not stain for either NCA or CEA in both normal and leukaemic subjects" and cross reactivity of the CEA antiserum with blood group antigens is eliminated during its purification by absorption with erythrocytes until agglutination is abolished. With regard to plasma CEA, bone scan, and x ray film findings, statistical evaluation was precluded by the small number of patients. It was noted, however, that the highest median plasma CEA concentration (70 ,ug/l) and the highest incidence of positive bone scans and x ray films occurred in the group of patients with histologically confirmed marrow metastases (Table 1) . These investigations failed to distinguish between patients in Tables 2 and 3. In conclusion, we have shown that the peroxidase-antiperoxidase method may be applied to bone marrow trephine sections which have been fixed, decalcified, and embedded in paraffin wax, although in our hands it was not suitable for use with bone marrow smears or clot secretions. The staining method is suitable for use in the histology laboratory of any general hospital and uses commercially available reagents. Since we have convincingly demonstrated the expression of CEA by carcinoma cells after they have metastasised to the marrow, the stain may prove useful in the interpretation of infiltrated marrows where the cell origin is difficult to identify-for example, in poorly differentiated lymphomas. In addition, we have identified a group of patients with small numbers of CEA positive cells, which may be indirectly or directly related to the Gray, Downing, Hill, Payne, Windsor presence of tumour in the marrow. The use of monoclonal antibodies may help to dispel any doubt over the specificity of the CEA antiserum, and follow up of patients should show any correlation between the presence of single, CEA positive cells within the marrow and prognosis, in particular, the subsequent development of overt marrow involvement.
